405 related articles for article (PubMed ID: 15735607)
1. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
3. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
[TBL] [Abstract][Full Text] [Related]
4. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.
Liu J; Liu ZQ; Yu BN; Xu FH; Mo W; Zhou G; Liu YZ; Li Q; Zhou HH
Clin Pharmacol Ther; 2006 Jul; 80(1):23-32. PubMed ID: 16815314
[TBL] [Abstract][Full Text] [Related]
5. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
[TBL] [Abstract][Full Text] [Related]
6. Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics.
Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
Pharmacogenomics J; 2006; 6(3):174-8. PubMed ID: 16402084
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
8. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy.
Magnusson Y; Levin MC; Eggertsen R; Nyström E; Mobini R; Schaufelberger M; Andersson B
Clin Pharmacol Ther; 2005 Sep; 78(3):221-31. PubMed ID: 16153393
[TBL] [Abstract][Full Text] [Related]
9. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
Gullestad L; Wikstrand J; Deedwania P; Hjalmarson A; Egstrup K; Elkayam U; Gottlieb S; Rashkow A; Wedel H; Bermann G; Kjekshus J;
J Am Coll Cardiol; 2005 Jan; 45(2):252-9. PubMed ID: 15653024
[TBL] [Abstract][Full Text] [Related]
10. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol.
Johnson JA; Zineh I; Puckett BJ; McGorray SP; Yarandi HN; Pauly DF
Clin Pharmacol Ther; 2003 Jul; 74(1):44-52. PubMed ID: 12844134
[TBL] [Abstract][Full Text] [Related]
11. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
12. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
13. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.
Biolo A; Clausell N; Santos KG; Salvaro R; Ashton-Prolla P; Borges A; Rohde LE
Am J Cardiol; 2008 Sep; 102(6):726-32. PubMed ID: 18773997
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of beta1 adrenergic receptor and their influence on the cardiovascular responses to metoprolol in a South Indian population.
Mahesh Kumar KN; Ramu P; Rajan S; Shewade DG; Balachander J; Adithan C
J Cardiovasc Pharmacol; 2008 Nov; 52(5):459-66. PubMed ID: 19033826
[TBL] [Abstract][Full Text] [Related]
15. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
16. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.
Pereira SB; Velloso MW; Chermont S; Quintão MM; Nunes Abdhala R; Giro C; Oliveira E Alves T; Camacho V; De Fátima Maia Contarato L; Pena FM; Balieiro HM; Garcia ML; Da Nóbrega AC; Ribeiro GS; Mesquita ET
Mol Med Rep; 2013 Jan; 7(1):259-65. PubMed ID: 23064657
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
18. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
Chan SW; Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
[TBL] [Abstract][Full Text] [Related]
19. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers.
Schwartz SG; Puckett BJ; Allen RC; Castillo IG; Leffler CT
Ophthalmology; 2005 Dec; 112(12):2131-6. PubMed ID: 16325708
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-blockade on baroreceptor and autonomic function in heart failure.
Sanderson JE; Yeung LY; Chan S; Tomlinson B; Kay R; Woo KS; Bernardi L
Clin Sci (Lond); 1999 Feb; 96(2):137-46. PubMed ID: 9918893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]